A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the rate of response with the combination of
erlotinib and bevacizumab in previously treated patients with thymoma or thymic carcinoma,
and to determine potential molecular markers that may predict response to therapy in patients
with thymoma or thymic carcinoma.